—Commenting on my editorial "Do I Take the Eye Out or Leave It In?" Dr Benson has raised a number of questions that are difficult to answer satisfactorily in a small space. The difficulty of providing quick answers becomes even more apparent when one considers that some of the best minds in ophthalmology, radiation oncology, epidemiology, biostatistics, and medical oncology have been struggling with some of these same questions for years. The issues raised are important, however, and I welcome the opportunity to address them. I believe that such dialogue is intellectually healthy for our specialty and that it can promote better patient care by enhancing the appreciation of how the randomized clinical trial can be used to assess new as well as standard therapies.Dr Benson begins by asserting that the COMS would be strong if certain experienced ophthalmologists had agreed to participate. These ophthalmologists were encouraged
Fine SL. Is the COMS Worthwhile?-Reply. Arch Ophthalmol. 1986;104(12):1746–1747. doi:10.1001/archopht.1986.01050240019005
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: